CAR陽(yáng)性表達(dá)率檢測(cè)是CAR-T療法質(zhì)量控制的重要一環(huán)，常用的檢測(cè)方案有利用Protein L、Anti-Fab抗體或靶點(diǎn)蛋白結(jié)合流式細(xì)胞術(shù)進(jìn)行檢測(cè)。其中，靶點(diǎn)蛋白結(jié)合流式細(xì)胞術(shù)的檢測(cè)方案因其靶點(diǎn)特異性強(qiáng)的優(yōu)勢(shì)而備受青睞，許多業(yè)內(nèi)人士預(yù)期靶點(diǎn)特異性的檢測(cè)將會(huì)被監(jiān)管機(jī)構(gòu)納入CAR-T質(zhì)量控制監(jiān)管考量的范疇。本文將對(duì)CAR陽(yáng)性表達(dá)率檢測(cè)相關(guān)案例做一匯總以供大家參考。

三種CAR-T陽(yáng)性率檢測(cè)試劑優(yōu)劣勢(shì)對(duì)比

檢測(cè)試劑檢測(cè)原理優(yōu)點(diǎn)缺點(diǎn)Protein L結(jié)合抗體 輕鏈成本低，且市面有能簡(jiǎn)化操作的直標(biāo)Protein L背景值高，無(wú)靶點(diǎn)特異性，不能檢測(cè)輕鏈 型CARAnti-Fab抗體結(jié)合抗體Fab段成本低，且市面有能簡(jiǎn)化操作的直標(biāo)抗體背景值高，無(wú)靶點(diǎn)特異性靶點(diǎn)蛋白特異性結(jié)合scFv抗原識(shí)別區(qū)具靶點(diǎn)特異性，且可以評(píng)估親和力成本相對(duì)高，不同靶點(diǎn)需建立不同方法，市面少有直標(biāo)靶點(diǎn)蛋白

案例匯總

 案例名稱數(shù)據(jù)來(lái)源 案例一利用生物素標(biāo)記hBCMA檢測(cè)anti-BCMA CAR陽(yáng)性表達(dá)率深圳普瑞金點(diǎn)擊查看案例二利用生物素標(biāo)記hCD19檢測(cè)anti-CD19 CAR陽(yáng)性表達(dá)率ACROBiosystems點(diǎn)擊查看案例三利用生物素標(biāo)記hCD19檢測(cè)anti-CD19 CAR陽(yáng)性表達(dá)率MacLeod DT點(diǎn)擊查看案例四利用hCD19, His Tag蛋白檢測(cè)anti-CD19 CAR陽(yáng)性表達(dá)率ACROBiosystems點(diǎn)擊查看案例五利用hCD19, Fc tag蛋白檢測(cè)anti-CD19 CAR陽(yáng)性表達(dá)率ACROBiosystems點(diǎn)擊查看案例六不同供應(yīng)商hCD19, Fc tag蛋白的結(jié)合特異性驗(yàn)證ACROBiosystems點(diǎn)擊查看

(點(diǎn)擊對(duì)應(yīng)案例即可跳轉(zhuǎn)案例詳情)

ACROBiosystems積極與CAR-T相關(guān)的醫(yī)藥研發(fā)人員緊密合作， 構(gòu)建CAR-T相關(guān)實(shí)驗(yàn)體系建設(shè)，如果您有CAR-T靶點(diǎn)的需求可以申請(qǐng)免費(fèi)試用，或?qū)σ韵路桨阜窒碛惺裁匆蓡?wèn)，可以及時(shí)，我們將持續(xù)分享該領(lǐng)域的成功案例以加速CAR-T藥物的研發(fā)進(jìn)程。

 

案例詳情

案例一、利用生物素標(biāo)記hBCMA檢測(cè)anti-BCMA CAR陽(yáng)性表達(dá)率 

返回案例匯總

應(yīng)用案例由深圳普瑞金生物藥業(yè)公司友情提供！

檢測(cè)方法：流式細(xì)胞術(shù)

檢測(cè)儀器：BD FACSCalibur流式細(xì)胞分析儀

樣本信息：轉(zhuǎn)染anti-BCMA CAR的人原代T淋巴細(xì)胞

主要試劑：

生物素標(biāo)記的hBCMA蛋白 (Biotinylated Human BCMA / TNFRSF17 Protein, Fc Tag, Avi Tag (Avitag ), ACROBiosystems, Cat.No. BC7-H82F0)；PE標(biāo)記的鏈霉親和素（PE Streptavidin , Biolegend, Cat.No. 405204)；

 

簡(jiǎn)要流程：

1. 將anti-BCMA CAR基因通過(guò)慢病毒質(zhì)粒轉(zhuǎn)染，整合到來(lái)自患者的自體T細(xì)胞基因中；2. 利用anti-BCMA CAR特異性結(jié)合BCMA蛋白的特性，將生物素標(biāo)記的hBCMA蛋白（ACROBiosystems, Cat.No. BC7-H82F0）標(biāo)記到anti-BCMA CAR-T細(xì)胞表面；3. 利用生物素特異性結(jié)合親和素的特性，將PE標(biāo)記的鏈霉親和素（Biolegend, Cat.No. 405204) 作為熒光二抗，標(biāo)記到anti-BCMA CAR-T細(xì)胞表面；4. 用BD FACSCalibur流式細(xì)胞分析儀進(jìn)行檢測(cè)分析。

 

檢測(cè)結(jié)果：結(jié)果顯示1號(hào)患者anti-BCMA-CAR T細(xì)胞陽(yáng)性率在52.72%，2號(hào)患者anti-BCMA-CAR T細(xì)胞陽(yáng)性率在73.49%.

FACS Analysis of anti-BCMA CAR expression

Human T cells were transfected with anti-BCMA CAR and cultured for 3 days. Three days post-transfection, 1x10 6 cells were first incubated with 50ul biotinylated human BCMA protein (Cat.No. BC7-H82F0, 8ug/ml ), washed and then stained with PE Streptavidin and analyzed by flow cytometry. (Data are kindly provided by PREGENE Biopharma)

相關(guān)產(chǎn)品：

BC7-H82F0 (Biotinylated Human BCMA, Fc Avi Tag)點(diǎn)擊申請(qǐng)Protocol點(diǎn)擊咨詢報(bào)價(jià)點(diǎn)擊分享新案例案例二、利用生物素標(biāo)記hCD19檢測(cè)anti-CD19 CAR陽(yáng)性表達(dá)率 

 

應(yīng)用案例由ACRO應(yīng)用開發(fā)團(tuán)隊(duì)自主研發(fā)提供！

檢測(cè)方法：流式細(xì)胞術(shù)

檢測(cè)儀器：NovoCyteTM Flow Cytometer, ACEA Biosciences

樣本信息：R1013-C6細(xì)胞(過(guò)表達(dá)Anti-CD19[FMC63] scFv RFP的Expi 293細(xì)胞)

主要試劑：

生物素標(biāo)記的hCD19蛋白 (Biotinylated Human CD19, Fc Tag, ultra sensitivity (primary amine labeling), ACROBiosystems, Cat.No.；FITC標(biāo)記的鏈霉親和素（FITC Streptavidin, Biolegend, Cat.No. 405201)；

 

簡(jiǎn)要流程：

1. 將Anti-CD19[FMC63] scFv RFP基因通過(guò)質(zhì)粒轉(zhuǎn)染，整合到Expi 293細(xì)胞基因中，命名為R1013-C6細(xì)胞；2. 利用anti-CD19[FMC63] scFv特異性結(jié)合CD19蛋白的特性，將生物素標(biāo)記的hCD19蛋白（ACROBiosystems, Cat.No. CD9-H8259）標(biāo)記到R1013-C6細(xì)胞表面；3. 利用生物素特異性結(jié)合親和素的特性，將FITC標(biāo)記的鏈霉親和素（FITC Streptavidin, Biolegend, Cat.No. 405201)作為熒光二抗，標(biāo)記到R1013-C6細(xì)胞表面；4. 用NovoCyteTM Flow Cytometer流式細(xì)胞分析儀進(jìn)行檢測(cè)分析。

 

檢測(cè)結(jié)果：結(jié)果顯示生物素標(biāo)記的CD19蛋白能夠與 R1013-C6細(xì)胞膜表面的anti-CD19 [FMC63] scFv特異性結(jié)合，這種結(jié)合能夠被游離的抗CD19的抗體FMC63拮抗。

FACS Analysis of anti-CD19 CAR expression

293 cells were transfected with FMC63-scFv and RFP tag . 2x105 of the cells were first incubated with A. Biotinylated protein control. B. Recombinant biotinylated human CD19 (Cat.No. CD9-H8259, 10ug/ml ) . C. Recombinant biotinylated human CD19 (Cat.No. CH8259, 10ug/ml) and FMC63(Mouse anti-CD19 antibody). FITC Streptavidin was used to analyse with FACS. RFP was used to evaluate CAR(FMC63-scFv) expression and FITC was used to evaluate the binding activity of recombinant biotinylated human CD19 (Cat.No. CD9-H8259) .

相關(guān)產(chǎn)品：

CD9-H8259 Biotinylated Human CD19, Fc Tag, ultra sensitivity (primary amine labeling)點(diǎn)擊申請(qǐng)Protocol點(diǎn)擊咨詢報(bào)價(jià)點(diǎn)擊分享新案例案例三、利用生物素標(biāo)記hCD19檢測(cè)anti-CD19 CAR陽(yáng)性表達(dá)率 

 

應(yīng)用案例來(lái)自 MacLeod DT, et al., 2017, Mol Ther. 25(4):949-961.doi: 10.1016/j.ymthe.2017.02.005.

檢測(cè)方法：流式細(xì)胞術(shù)

檢測(cè)儀器：BD Fortessa flow cytometer (BD Biosciences)

樣本信息：TRC1-2-treated, AAV:TRAC:CAR-transduced T cells

主要試劑：

生物素標(biāo)記的hCD19蛋白 (Biotinylated Human CD19, Fc Tag, ultra sensitivity (primary amine labeling), ACROBiosystems, Cat.No. CD9-H8259)；PE標(biāo)記的鏈霉親和素（PE Streptavidin, Biolegend)；Anti-CD3-BV711抗體（Brilliant Violet 711 anti-human CD3 Antibody, BioLegend).

 

簡(jiǎn)要流程：

1. 利用CD19 CAR能特異性結(jié)合CD19蛋白的特性，如果待檢T細(xì)胞正常表達(dá)了CD19 CAR，生物素標(biāo)記的CD19-Fc蛋白就能被標(biāo)記到待檢T細(xì)胞表面；2. 利用生物素能特異性結(jié)合親和素（PE Streptavidin）和Anti-CD3-BV711抗體能特異性結(jié)合CD3分子的特性，如果待檢T細(xì)胞表面有生物素和CD3分子，鏈霉親和素上的PE和Anti-CD3抗體上的BV711熒光標(biāo)記就能被標(biāo)記到待檢T細(xì)胞表面；3. 將制備好的單細(xì)胞懸液上機(jī)進(jìn)行流式細(xì)胞分析。

 

檢測(cè)結(jié)果：結(jié)果顯示CD3陰性T細(xì)胞群中CD19 CAR表達(dá)的比例要高于CD3陽(yáng)性T細(xì)胞群。

FACS Analysis of anti-CD19 CAR expression

Activated T cells were electroporated with TRC1-2 mRNA and transduced with AAV:TRAC:CAR at an MOI of 400,000 vg/cell and cultured for 5 days in the presence of IL-2. Five days post-transduction, cells were stained for expression of the CAR using abiotinylated CD19-Fc reagent and CD3, with TRC1-2-treated, mock-transduced cells used as a control for gating of CAR expression. CD3+ cells were then depleted. Enriched CD3 cells were cultured for 3 additional days in the presence of IL-15 and IL-21 and then analyzed again by flow cytometry for CD3 and CAR expression.

相關(guān)產(chǎn)品：

CD9-H8259 Biotinylated Human CD19, Fc Tag, ultra sensitivity (primary amine labeling)點(diǎn)擊咨詢報(bào)價(jià)點(diǎn)擊分享新案例案例四、利用hCD19, His Tag蛋白檢測(cè)anti-CD19 CAR陽(yáng)性表達(dá)率 

返回案例匯總

驗(yàn)證數(shù)據(jù)由ACRO應(yīng)用開發(fā)團(tuán)隊(duì)自主研發(fā)提供！

檢測(cè)方法：流式細(xì)胞術(shù)

細(xì)胞樣本：R1013-C6 cells (過(guò)表達(dá)Anti-CD19[FMC63] scFv RFP的Expi 293細(xì)胞)

主要試劑：

Human CD19, His Tag蛋白（ACROBiosystems, Cat.No. CD9-H52H2）；FITC anti-6xHis tag antibody（Abcam, Cat.No. ab1206）.

 

簡(jiǎn)要流程：

1. 將anti-CD19[FMC63] scFv RFP基因通過(guò)質(zhì)粒轉(zhuǎn)染，整合到Expi 293細(xì)胞基因中，命名為R1013-C6細(xì)胞；2. 利用anti-CD19[FMC63] scFv特異性結(jié)合CD19蛋白的特性，將hCD19, His Tag蛋白（ACROBiosystems, Cat.No. ）標(biāo)記到R1013-C6細(xì)胞表面；3. 將熒光二抗FITC anti-6xHis tag antibody （Abcam, Cat.No. ab1206）標(biāo)記到R1013-C6細(xì)胞表面；4. 用Accuri C6 Flow Cytometer流式細(xì)胞分析儀進(jìn)行檢測(cè)分析。

 

檢測(cè)結(jié)果：結(jié)果顯示hCD19, His Tag蛋白能夠與 R1013-C6細(xì)胞膜表面的anti-CD19 [FMC63] scFv特異性結(jié)合，這種結(jié)合能夠被游離的抗CD19的抗體FMC63拮抗。

FACS Analysis of anti-CD19 CAR expression

293 cells were transfected with FMC63-scFv and RFP tag . 2x105 of the cells were first incubated with A. His Tag-protein control. B. Recombinant His Tag-human CD19  C. The mixture of recombinant His Tag-human CD19 ( and FMC63(Mouse anti-CD19 antibody), followed by FITC anti-6xHis tag antibody, and then analyzed using Accuri C6 Flow Cytometer. RFP was used to evaluate CAR(FMC63-scFv) expression and FITC was used to evaluate the binding activity of recombinant His Tag-human CD19 (Cat.No. ).

相關(guān)產(chǎn)品：

 (Human CD19 Protein, His Tag)點(diǎn)擊申請(qǐng)Protocol點(diǎn)擊咨詢報(bào)價(jià)點(diǎn)擊分享新案例案例五、利用hCD19, Fc tag蛋白檢測(cè)anti-CD19 CAR陽(yáng)性表達(dá)率 

 

驗(yàn)證數(shù)據(jù)由ACRO應(yīng)用開發(fā)團(tuán)隊(duì)自主研發(fā)提供！

檢測(cè)方法：流式細(xì)胞術(shù)

細(xì)胞樣本：R1013-C6 cells (過(guò)表達(dá)Anti-CD19[FMC63] scFv RFP的Expi 293細(xì)胞)

主要試劑：

Human CD19, Fc tag蛋白 （Acrobiosystems, Cat.No. ）；FITC anti-human IgG Fc antibody ( Biolegend, Cat.No. 409310）.

 

簡(jiǎn)要流程：

1. 將anti-CD19[FMC63] scFv RFP基因通過(guò)質(zhì)粒轉(zhuǎn)染，整合到Expi 293細(xì)胞基因中，命名為R1013-C6細(xì)胞；2. 利用anti-CD19[FMC63] scFv特異性結(jié)合CD19蛋白的特性，將hCD19, Fc tag蛋白（Acrobiosystems, Cat.No.）標(biāo)記到R1013-C6細(xì)胞表面；3. 將熒光二抗FITC anti-human IgG Fc antibody ( Biolegend, Cat.No. 409310）標(biāo)記到R1013-C6細(xì)胞表面；4. 用NovoCyteTM Flow Cytometer流式細(xì)胞分析儀進(jìn)行檢測(cè)分析。

 

檢測(cè)結(jié)果：結(jié)果顯示hCD19, Fc tag蛋白能夠與 R1013-C6細(xì)胞膜表面的anti-CD19 [FMC63] scFv特異性結(jié)合，這種結(jié)合能夠被游離的抗CD19的抗體FMC63拮抗。

FACS Analysis of anti-CD19 CAR expression

293 cells were transfected with FMC63-scFv and RFP tag . 2x105 of the cells were first incubated with A. Human Fc tag control. B. Recombinant human CD19,Fc Tag (Cat.No., 10ug/ml ). C. Recombinant human CD19,Fc Tag(Cat.No. , 10ug/ml ) and FMC63(Mouse anti-CD19 antibody) . The FITC anti-human IgG Fc was used to analyse with FACS. RFP was used to evaluate CAR(FMC63-scFv) expression and FITC was used to evaluate the binding activity of recombinant human CD19,Fc Tag .

相關(guān)產(chǎn)品：

 (Human CD19 Protein, Fc Tag)點(diǎn)擊申請(qǐng)Protocol點(diǎn)擊咨詢報(bào)價(jià)點(diǎn)擊分享新案例案例六、不同供應(yīng)商hCD19, Fc tag蛋白的結(jié)合特異性驗(yàn)證 

 

驗(yàn)證數(shù)據(jù)由ACRO應(yīng)用開發(fā)團(tuán)隊(duì)自主研發(fā)提供！

檢測(cè)方法：流式細(xì)胞術(shù)

細(xì)胞樣本： R1013-C6 cells (過(guò)表達(dá)Anti-CD19[FMC63] scFv RFP的Expi 293細(xì)胞)；Expi 293 cells；Jurkat E6.1 cells.

主要試劑：

蛋白樣本1：Human CD19 Protein, Fc Tag (ACROBiosystems, Cat.No.);蛋白樣本2：Human CD19 Protein, Fc Tag (Company N)；陰性對(duì)照蛋白：Human PD-L1 Protein, Fc Tag (ACROBiosystems, Cat.No. 熒光二抗：FITC anti-human IgG Fc antibody (Biolegend, Cat.No. 409310).

 

簡(jiǎn)要流程：

1. 用Human CD19 Fc tag蛋白分別標(biāo)記R1013-C6 細(xì)胞、Expi 293細(xì)胞和Jurkat E6.1細(xì)胞；2. 將FITC anti-human IgG Fc antibody作為熒光二抗，對(duì)以上細(xì)胞進(jìn)行二次標(biāo)記；3. 用NovoCyteTM Flow Cytometer流式細(xì)胞分析儀進(jìn)行檢測(cè)分析。

 

檢測(cè)結(jié)果：結(jié)果顯示ACROBiosystems的Human CD19 Protein, Fc Tag蛋白僅能特異性識(shí)別R1013-C6細(xì)胞表面的Anti-CD19[FMC63] scFv，不能與Expi 293細(xì)胞和Jurkat E6.1細(xì)胞發(fā)生非特異性結(jié)合反應(yīng)；而同等實(shí)驗(yàn)條件下，Company N的Human CD19 Protein, Fc Tag蛋白與Expi 293細(xì)胞和Jurkat E6.1細(xì)胞發(fā)生了較強(qiáng)的非特異性結(jié)合。

Binding specificity analysis of ACROBiosystems hCD19(C-Fc tag) protein

FACS analysis of human CD19 protein, Fc Tag (ACROBiosystems, Cat.No.) binding to A. R1013-C6 cells, B. Expi 293 cells, C. Jurkat E6.1 cells. Cells were first stained with human CD19 protein, Fc Tag (ACROBiosystems, Cat.No. followed by FITC anti-human IgG Fc antibody, and then analyzed using NovoCyteTM Flow Cytometer. The data were analyzed with FCS Express 6Plus and GraphPad Prism 5 software.

Binding specificity analysis of Company N hCD19(C-Fc tag) protein

FACS analysis of human CD19 protein, Fc Tag (Company N) binding to A. R1013-C6 cells, B. Expi 293 cells, C. Jurkat E6.1 cells. Cells were first stained with human CD19 protein, Fc Tag (Company N) followed by FITC anti-human IgG Fc antibody, and then analyzed using NovoCyteTM Flow Cytometer. The data were analyzed with FCS Express 6Plus and GraphPad Prism 5 software.

相關(guān)產(chǎn)品：

CD9-H5259 (Human CD19 Protein, Fc Tag)點(diǎn)擊申請(qǐng)Protocol點(diǎn)擊咨詢報(bào)價(jià)點(diǎn)擊分享新案例參考文獻(xiàn)(1) MacLeod DT, et al., 2017, Mol Ther. 25(4):949-961.doi: 10.1016/j.ymthe.2017.02.005.. 

關(guān)注本網(wǎng)官方微信 隨時(shí)閱讀專業(yè)資訊